Grifols, S.A. (GRFS) on Decifer

Decifer ranks GRFS number 216 of 277 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 5% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 6% a year, profits grew 148% over the past year, and growth is speeding up, not slowing down.
• It keeps a healthy share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It sits in a part of the market we are watching.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Profits up 148% and widening margins in a leading healthcare sector are notable, but returns near 5%, revenue growing only about 6% a year and momentum of 7 out of 35 hold it back.

The current read

The evidence on GRFS lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Grifols, S.A. operates in drug manufacturers - general. That places it inside the Healthcare, Biotech & Devices story.

Read the full GRFS research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.